Sort   by:  
 Page size 
TranscriptomicsUPC2 Is universally essential for Azole antifungal resistance in Candida albicans
In Candida albicans, the transcription factor Upc2 is central to the regulation of ergosterol biosynthesis. UPC2-activating mutations contribute to azole resistance, whereas disruption increases azole susceptibility. In the present study, we investigated the relationship of UPC2 to fluconazole susce...
ORGANISM(S): Candida albicans 
2014-05-24 | E-GEOD-57929 | biostudies-arrayexpress
TranscriptomicsUp-regulation of ERG11 is prevalent among azole-resistant clinical isolates of Candida albicans and is only partially explained by gain-of-function mutations in UPC2
In Candida albicans, Upc2 is a zinc-cluster transcription factor that targets genes including those of the ergosterol biosynthesis pathway. To date there have been three documented UPC2 gain-of-function (GOF) mutations recovered from fluconazole-resistant clinical isolates that contribute to an inc...
ORGANISM(S): Candida albicans 
2013-01-31 | E-GEOD-39201 | biostudies-arrayexpress
UnknownThe REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial.
Not available
S-EPMC5838871 | biostudies-literature
UnknownSimvastatin in Critically Ill Patients with Covid-19.
Not available
S-EPMC10755839 | biostudies-literature
UnknownEffects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage: Extended Follow-up of the RESTART Randomized Clinical Trial.
Not available
S-EPMC8417806 | biostudies-literature
UnknownEnhancing cognitive performance prediction by white matter hyperintensity connectivity assessment.
Not available
S-EPMC11629703 | biostudies-literature
UnknownEffect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC10326520 | biostudies-literature
UnknownEffect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC8941448 | biostudies-literature
UnknownLong-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Not available
S-EPMC9857594 | biostudies-literature
Sort   by:  
 Page size